Cargando…

High levels of anti–SARS-CoV-2 IgG antibodies in previously infected patients with cancer after a single dose of BNT 162b2 vaccine

Detalles Bibliográficos
Autores principales:	Fong, Dominic, Mair, Maximilian J., Mitterer, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192959/ https://www.ncbi.nlm.nih.gov/pubmed/34217909 http://dx.doi.org/10.1016/j.ejca.2021.05.036

Ejemplares similares

Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers
por: Fong, Dominic, et al.
Publicado: (2021)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2022)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
por: Rechavi, Yoav, et al.
Publicado: (2021)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection
por: Pratò, Simone, et al.
Publicado: (2021)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
por: Lau, Chin Shern, et al.
Publicado: (2022)

IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity
por: Bates, John T., et al.
Publicado: (2022)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination
por: Cimas, Francisco J., et al.
Publicado: (2023)

Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster
por: Salvagno, G.L., et al.
Publicado: (2022)

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan
por: Sakamoto, Atsuhiko, et al.
Publicado: (2022)

Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
por: Danese, Elisa, et al.
Publicado: (2021)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2
por: Fujigaki, Hidetsugu, et al.
Publicado: (2022)

Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
por: Li, Jiaqi, et al.
Publicado: (2023)

Re: ‘Association between IgG antibody levels and adverse events after first and second BNT162b2 mRNA vaccine doses’ by Braun et al
por: Zhou, Yuchi, et al.
Publicado: (2022)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
por: Hamaya, Tomoko, et al.
Publicado: (2022)

Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers
por: Korodi, Mónika, et al.
Publicado: (2022)

Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
por: Higashimoto, Yuki, et al.
Publicado: (2022)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
por: Hickey, Thomas E., et al.
Publicado: (2023)

Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults
por: Rastawicki, Waldemar, et al.
Publicado: (2022)

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?
por: Takeuchi, Masaaki, et al.
Publicado: (2021)

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose
por: Đaković Rode, Oktavija, et al.
Publicado: (2022)

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine
por: Wan Shuaib, Wan Muhammad Azfar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_igkipr6ulc965duu6c9pk9hm72